KOLMAR-BNH
21.6.2024 08:01:29 CEST | Business Wire | Press release
Kolmar BNH (KOSDAQ: 200130), a leading Original Development Manufacturing (ODM) company for health functional foods, strengthens its market position by acquiring certification for the additional functionality of HemoHIM, a renowned Korean health supplement.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240620376394/en/
HemoHIM G, manufactured by Kolmar BNH and distributed by Atomy, contains Angelica sinensis, Ligusticum chuanxiong, and Paeonia lactiflora. It was launched in Taiwan last month. (Photo: Kolmar BNH)
The company secured approval from the Ministry of Food and Drug Safety for the fatigue-improving function of the HemoHIM extract complex of angelica gigas, etc., derived from angelica gigas and other components in 2023. This achievement was made six years after the launch of its HemoHIM Sustainable Technology Development Project. As a result, HemoHIM came to the market as a dual-functional health product designed to boost immune function and reduce fatigue.
HemoHIM, developed by Kolmar BNH in 2006, is the nation’s first individually-approved immune-boosting health supplement, formulated using indigenous natural ingredients like angelica gigas, cnidium officinale, and paeonia japonica. Distributed by Atomy, it's now a global success, exported to over 20 countries and generating over KRW 2 trillion in sales with exports exceeding $200 million. It has remained Korea's top-selling immune booster for over a decade.
Kolmar BNH validated the fatigue improvement function of HemoHIM through extensive clinical (human trials) and non-clinical trials (cell tests). In trials involving adults aged 30 to 59 experiencing fatigue, significant enhancements were observed in fatigue measures, including the Fatigue Severity Scale (FSS) and Multidimensional Fatigue Inventory (MFI), following consumption of the HemoHIM extract complex of angelica gigas, etc. These findings were published in Phytomedicine Plus, an international journal dedicated to natural medicine, with patents registered in Korea and Russia.
Continuing its commitment to innovation following the launch of HemoHIM, Kolmar BNH allocates over 2% of its annual sales to R&D. This investment aims to enhance product functionality and fortify competitive advantage.
HemoHIM G, targeting the global market, is one of the results of such dedication to R&D. Launched in Taiwan last month, HemoHIM G is a new product for export that has made meticulous adjustments to its raw materials and ingredient proportions to comply with international food regulations. Its key ingredients such as Angelica sinensis, Ligusticum chuanxiong, and Paeonia lactiflora went through rigorous sourcing procedures and stringent quality control. The taste and aroma profiles were tailored to suit the preferences of global consumers. Furthermore, its safety has been certified in the prestigious academic journal “Toxicological Research”, accredited at the SCIE level.
Kolmar BNH official said, "Through relentless research and development efforts, Kolmar BNH has enhanced the competitiveness of HemoHIM. We are dedicated to promoting K-health functional food globally through ongoing innovations in HemoHIM."
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240620376394/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Strategic Combination of ITC Infotech and Happiest Minds Technologies to Create a Scaled, Future-Ready, AI-First Global Technology Services Enterprise with US$ 1 Billion Revenue by FY28[1]31.8.2026 23:35:00 CEST | Press release
ITC Infotech Board approves proposed acquisition of 22.1% promoter stake and a Scheme of Amalgamation of the two companies ITC Infotech (ITCI), a wholly owned subsidiary of ITC Limited and a leading global technology services player, today announced the proposed strategic combination with Happiest Minds Technologies Limited (Happiest Minds) to create a scaled, future-ready, AI-first global technology services enterprise. The ITCI Board approved a proposal to acquire 22.1% equity stake from the promoter of Happiest Minds in two tranches under a Share Purchase Agreement. The transaction would be funded through a Rights Issue by ITC Infotech. ITCI Board has also approved a proposed Scheme of Amalgamation of Happiest Minds with ITCI which will be effected after the share acquisition. Pursuant to the scheme, the shares of ITCI will be listed on the stock exchanges. The proposed transaction has also been endorsed by the Board of Directors of ITC Limited. This strategic combination will syner
Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 21:07:00 CEST | Press release
Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 21:00:00 CEST | Press release
Agreement advances patient access and strengthens BeOne's long-term commitment to U.S. innovation and manufacturing BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional res
MEX Exchange, Part of MultiBank Group, Announces Senior Leadership Appointments31.8.2026 15:36:00 CEST | Press release
David Ogg appointed Vice Chairman and Brian Andreyko named CEO MEX Exchange, the institutional electronic trading platform of MultiBank Group, has announced two senior leadership appointments, with David Ogg promoted to Vice Chairman and Brian Andreyko promoted to Chief Executive Officer. The appointments strengthen the company’s leadership as it advances the development of its institutional electronic trading platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831401493/en/ MEX Exchange, part of MultiBank Group, Announces Senior Leadership Appointments with David Ogg appointed Vice Chairman and Brian Andreyko named CEO. David Ogg brings more than four decades of experience in foreign exchange trading and trading technology and is widely recognised within the institutional FX industry as the “Father of the ECN.” He founded HotspotFX in 1999, the first institutional FX electronic communications network, before going o
Rimini Street Announces Stock Repurchase and Debt Reduction Transactions31.8.2026 15:00:00 CEST | Press release
The Company recently completed an additional $5.0 million of common stock repurchases and $5.0 million of debt prepayment that brings total fiscal year-to-date capital return and balance sheet optimization to $30.9 million Rimini Street, Inc., (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced additional, recent capital return and balance sheet optimization actions as noted below during the fiscal third quarter through August 28, 2026: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831961587/en/ Rimini Street Announces Stock Repurchase and Debt Reduction TransactionsDebt Reduction: The Company prepaid $5.0 million of its term loan and has reduced term loan debt by a total of $25.9 million fiscal year-to-date, reducing the outstanding balance t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom